High call volume says your rep was busy, not that the call was any good

The pharma sales KPIs worth tracking fall into five groups: activity (calls, reach and frequency), call quality and capability (message delivery, objection handling and compliance), customer engagement, readiness, and outcomes such as prescriptions and share. Call volume, the number most dashboards lead with, belongs to the first group and says the least on its own. It tells you a rep was busy. It does not tell you whether anything they said was accurate, balanced or worth a physician's time.

This article is for sales leaders, commercial excellence and sales operations teams, and the first-line managers who live with the scorecard. It covers what each group of metrics can and cannot tell you, why attributing prescriptions to a single rep is so hard, the difference between leading and lagging indicators, how to measure readiness, how to keep metrics from pushing reps toward compliance shortcuts, and an example scorecard. It gives no benchmarks, because targets depend on therapy area, access and selling model, and it is not legal advice.

What are activity metrics, and where do they stop being useful?

Activity metrics count what reps do. The common ones are calls (total interactions in a period), reach (the share of the target list a rep has seen at least once) and frequency (how often each target is seen). Many teams add call plan adherence: whether the rep saw the physicians the targeting model prioritized.

They are useful in one specific way. Reach and frequency on the right targets tell you whether a rep's effort is pointed at the physicians who matter. A rep with high volume and low reach on priority targets is busy with the wrong people, and that is worth a conversation.

Their limits are just as specific. Activity measures effort, not effect. A quick drop-off at the front desk and a ten-minute clinical discussion can count as the same call. Volume targets are easiest to hit in friendly, accessible offices, while in offices that restrict rep access the most valuable calls are the hardest to get, and so the least likely to show up in the count. Reward volume alone and you get more of the easy calls.

How do you measure the quality of a rep's calls?

Quality metrics ask what happened in the call. Three matter most. Message delivery: did the rep present the core message accurately, with the right population, endpoint and time frame? Objection handling: when the physician pushed back, did the rep clarify the concern and answer it with approved information? Compliance: was every statement on label, was risk information presented in balance, and were out-of-scope questions referred to Medical?

Quality is harder to count than calls, which is why so many scorecards leave it out. There are two workable sources. Field observation, through ride-alongs and coaching reports, gives real calls but a small and uneven sample. Scored practice calls give a larger, consistent sample against the same scenario, but they are practice. Used together, each covers the other's blind spot.

Both depend on a shared rubric and calibrated managers. If one district rates generously and another strictly, the quality score measures the manager, not the rep. How to get managers scoring the same way is covered in our guide to pharma sales coaching.

Which customer engagement metrics are worth tracking?

Engagement metrics look at what the physician does, not the rep. Useful ones include follow-ups the physician agreed to and whether they happened, requests for approved materials or a call with a medical science liaison, engagement with approved email the rep sent after a visit, and whether the office gives the rep more time on the next call or less.

These are signals of a relationship that is working, and they move earlier than prescriptions. They are also noisy. Engagement depends on the specialty, the office and the time of year, so compare a rep with their own trend and with similar territories, not with a company average.

Some engagement numbers should never be targets. A medical information request is a good sign when a rep refers an off-label question properly, but a target for them would reward reps for steering conversations toward off-label topics. Meals and other transfers of value to physicians are reported by manufacturers to CMS's Open Payments program and published, so a metric that rewards lunches booked rewards a cost, a compliance exposure and a public record all at once.

Why is it so hard to attribute prescriptions to one rep?

Outcome metrics are what the business runs on: new and total prescriptions, market share and sales in the territory. They are also the hardest to pin on a single rep, for reasons that have nothing to do with effort.

A physician's prescribing moves with formulary status and prior authorization rules, treatment guidelines, colleagues, conference data, DTC advertising, the patients who come in that month and the competitor that just launched. Many accounts are also seen by more than one person from the same company: a rep from another product team, a key account manager, an MSL. Prescription data commonly comes from third-party data providers and arrives after a delay, and at the level of a single prescriber the numbers are often too small to show a reliable trend.

None of this means outcomes do not matter. It means they belong at the territory or team level, measured against the territory's own baseline, adjusted for changes in access, and reviewed over quarters rather than weeks. Judging a rep on a month of prescriber-level data rewards luck and territory alignment as much as skill.

What are leading and lagging indicators in pharma sales?

Lagging indicators tell you what already happened: prescriptions, share, revenue. By the time they move, the calls behind the movement are weeks or months old. Leading indicators move first and can still be acted on: readiness, call quality, reach on priority targets and engagement.

Readiness is the leading indicator most teams do not measure. It answers a simple question: can this rep hold a full conversation with a skeptical physician, on label, today? It can be measured the same way for everyone, with a scored conversation against a consistent physician persona and a rubric that covers both selling skill and compliance, broken down by skill. That makes it comparable across reps, districts and launch cohorts, which a knowledge exam is not, as we argue in why quiz scores don't predict rep readiness.

Readiness matters most before a launch or a label change, when there are no outcomes yet to look at. A field force that is not ready on launch day shows up in the lagging indicators months later, when it is far more expensive to fix.

How do you build a pharma sales scorecard that doesn't reward cutting corners?

Start from the fact that every metric is an incentive. HHS OIG's General Compliance Program Guidance, published in November 2023, asks compliance committees to consider whether sales goals may inadvertently encourage risky or noncompliant behavior, and whether performance goals may have unintended consequences such as falsified documents. It also says achievements in compliance should be treated commensurately with achievements in other areas. The patterns are predictable: volume targets reward short calls and calls logged that barely happened, and attendance targets for speaker programs run into the red flags in OIG's 2020 Special Fraud Alert on speaker programs, which include sales and marketing influence over speaker selection and repeat attendees with no legitimate reason to attend.

A balanced scorecard puts one or two measures from each group side by side, so no single number decides how a rep is doing. One example, with targets set from your own baseline rather than an industry average: reach and frequency on priority targets against the call plan; field observations and scored practice calls on the brand's priority skills, against one calibrated rubric; agreed follow-ups completed; a scored readiness conversation on the current core message and its most common objections, refreshed at each launch or label change; and territory prescriptions and share against the territory's own baseline, reviewed quarterly.

Make compliance a gate, not a weighted score: required training complete, adverse events reported on time, expenses documented accurately, and no substantiated promotional violations. A strong sales number should never be able to offset an off-label call. Pair every activity metric with a quality metric, so volume without substance does not score, and have compliance and legal review the scorecard before it ships, as they would any other incentive plan.

Use the scorecard to start conversations, not to rank. A rep with strong reach and weak quality needs coaching, not a lower bonus. A rep with strong quality and flat outcomes in a territory that just lost formulary access may be doing everything right. Ranking everyone on one composite number across the whole company invites the same problems as a company-wide leaderboard.

Where SwishX fits

Magic Academy makes call quality and readiness measurable before they show up in the lagging numbers. Reps practise in voice or text against a generated HCP persona for their therapy area and the physician's specialty, and every call is scored against the same claims-linked, fair-balance, on-label rubric that governs the brand's content, including MSL and off-label question handling. Compliance is scored in the same call as selling skill.

Each rep's scored calls build into a Rep Dossier, and managers see readiness by team, region or launch cohort, with a gamified leaderboard organized in district-matched leagues rather than one company-wide ranking. See how it fits next to your existing scorecard on the Magic Academy page.

Frequently asked questions